59, 1
• Use in lactation: It is unknown whether molnupiravir or any of the components of molnupiravir are present in human milk, affect human milk production, or have effect on the breastfed infant
Molnupiravir is a white to off-white solid that is soluble in water
7% in molnupiravir vs
7% in May 3, 2021 · We evaluated molnupiravir (EIDD-2801/MK-4482), for the treatment of COVID-19 in a seamless phase I/II trial
Breastfeeding is not recommended during treatment and for four (4) days after the last dose of molnupiravir
We have shown that a dose of 800 mg of molnupiravir twice daily is safe
Potential clinically significant interaction that is likely to require additional monitoring
(See Summary) View all available interactions with Molnupiravir by clicking here
Compare Molnupiravir head-to-head with other drugs for uses, ratings, cost, side effects